Condition
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Total Trials
2
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
5 treatments under study, led by Cadonilimab
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2 (1)
Phase 3 (1)
Trial Status
Active Not Recruiting1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT04848753Phase 3Active Not RecruitingPrimary
Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
NCT07263919Phase 2RecruitingPrimary
Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
Showing all 2 trials
Research Network
Common Treatments
- Cadonilimab1
- Cisplatin1
- Placebo Combined With Cisplatin And Paclitaxel1
- Toripalimab Combined With Cisplatin And Paclitaxel1
- Paclitaxel1
Active Sponsors
- Akeso1
- Shanghai Junshi Bioscience Co., Ltd.1
Top Investigators
Peking University Cancer Hospital & Institute
Peking University Cancer Hospital & Institute
The Second Affiliated Hospital of Air Force Military Medical University
Henan Cancer Hospital